Lakewood-Amedex reports positive antimicrobial resistance data for Nu-3 diabetic foot ulcer drug

Lakewood-Amedex Biotherapeutics Inc.

Lakewood-Amedex Biotherapeutics Inc.

LABT

0.00
  • Lakewood-Amedex Biotherapeutics announced positive laboratory resistance findings for Nu-3, its lead topical candidate for infected diabetic foot ulcers.
  • Results have already been generated from studies designed to promote resistance over 21 days.
  • Nu-3 largely retained antimicrobial activity in these tests, supporting company expectations for low resistance risk versus standard antibiotics.
  • Data also indicated no cross-resistance in bacteria that became resistant to ciprofloxacin, reinforcing Nu-3 positioning for drug-resistant infections.
  • Lakewood-Amedex is also evaluating its Bisphosphocin class in preclinical work for complicated urinary tract infection and pulmonary infections.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lakewood-Amedex Biotherapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202605010802PR_NEWS_USPR_____NY48616) on May 01, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.